$131.92
-1.15 (-0.86%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where TFX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 4 observational · 3 with posted results
Held by 15 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, BAUPOST GROUP LLC/MA, CITADEL ADVISORS LLC, Holocene Advisors, LP, Balyasny Asset Management L.P., +10 more) · FINRA short interest 7.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Clinical Registry to Demonstrate the Safety and Performance of Teleflex Vascular Access DevicesNCT06604039observationalCatheter devices: successful use of the device without removal due to device-related adverse events | — | Recruiting | Device: Central venous catheter | Vascular Access Device | 2,500 | 2034-12-07 | in 3,032 d | 2026-08-11 |
| Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery LesionsNCT07258290Target Lesion Failure (TLF) rate at 12 months post-index procedureRandomized · Single-masked · Treatment | Not applicable | Recruiting | Device: Freesolve RMS, Xience DES | Coronary Disease, Heart Diseases, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Vascular Diseases, Chest Pain, Pain, Neurologic Manifestations, Signs and Symptoms, Pathological Conditions, Signs and Symptoms, Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Angina Pectoris | 1,859 | Jun 2029 | ≤ 1,046 d | 2026-07-24 |
| Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery LesionsNCT06779630Target Lesion Failure (TLF) rate at 12 months post-index procedureOpen-label · Treatment | Not applicable | Recruiting | Device: Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System | Coronary Artery Disease | 150 | Sep 2027 | ≤ 407 d | 2026-07-24 |
| AE05ML Device for ML Hem-o-lok Polymer Clip Delivery in Laparoscopic Surgical Procedures Observational Registery StudyNCT06364865observationalEvaluating the safety of AE05ML | — | Completed | Device: laparoscopic procedure | Gall Bladder Disease, Bile Duct Diseases, Acute Cholecystitis, Kidney, Liver, Appendix, Spleen Disease, Prostate | 161 | 2025-02-27actual | — | 2026-05-11 |
| Vascular Positioning System G4 Algorithm ECG Data Collection for Model Training StudyNCT05702515results2025-04-08observationalVPS G4 System Digital Data vs GE MAC 5500 Ecg Machine DataStudy Protocol and Statistical Analysis Plan ↗ | — | Completed | Other: Digital ECG Data Collection | Peripheral ICC | 27 | 2024-06-26actual | — | 2025-04-08 |
| Comparing Arrow PICC Catheters w/ Arrowga+rd Blue Advanced Protection Performance and Safety to Unprotected PICC'sNCT05278507First attempt PICC insertion successRandomized · Open-label · Other | Not applicable | Unknown status | Device: Arrowga+rd Blue Advance Protection PICC Placement, Sham Comparator PICC placement | Peripherally Inserted Central Catheter | 444 | 2023-06-30 | — | 2023-01-23 |
| Clinical Trial Assessing Non-Inferiority of Freeze Dried Plasma to Fresh Frozen Plasma in Reversing WarfarinNCT04794348Relative change in International Normalized Ratio (INR)Randomized · Quadruple-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: This study was never started and is no longer planned for execution. We are now in the process of aligning to a new study design with the FDA. | Biological: Fresh Frozen Plasma (FFP), Freeze Dried Plasma (FDP) | Anticoagulant Reversal | 0 | Mar 2022 | — | 2026-04-02 |
| Arrow Chloragard Peripherally-Inserted Central Catheters (PICC) StudyNCT03019302Incidence of symptomatic and asymptomatic catheter-related venous thrombosis (CVRT)Open-label · Supportive care | Not applicable | Unknown status | Device: Arrow PICC with Chloragard Technology | Vascular Access Complication, Vascular Access Related Infection | 100 | Aug 2017 | — | 2017-03-27 |
| Evaluation and Control of WAG in PACU Within Patient and Caregiver Breathing ZoneNCT02428413results2016-09-29Waste Anesthetic Gas Measured by Parts Per Million Within PACU Caregiver's Breathing Zone With Caring for PatientsRandomized · Open-label | Not applicable | Completed | Device: ISO-Gard Mask, Standard oxygen mask | Waste Anesthetic Gas (WAG) Emanating From Patients Post-operative Recovery | 125 | Nov 2015actual | — | 2016-11-25 |
| Observational Study of Complications Related to Use of Peripherally Inserted Central CathetersNCT01578993results2014-06-24observationalRate of PICC Line Occlusions | — | Completed | — | Adult Patients With Peripherally Inserted Central Catheters | 101 | Jun 2013actual | — | 2016-03-16 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19